<DOC>
	<DOCNO>NCT02431351</DOCNO>
	<brief_summary>This open-label study design evaluate safety efficacy selective inhibitor nuclear export ( SINE ) compound , Selinexor give orally patient transfusion-dependent , EPO-refractory lower-risk MDS ( Low risk Intermediate-1 define IPSS ) .</brief_summary>
	<brief_title>Efficacy &amp; Safety Study KPT-330 Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients</brief_title>
	<detailed_description>This single-arm , open-label , study design evaluate safety efficacy selective inhibitor nuclear export ( SINE ) compound , Selinexor give orally patient transfusion-dependent , EPO-refractory lower-risk MDS ( Low risk Intermediate-1 define IPSS ) . Patients dose clinic clinic visit day receive Selinexor dose home additional day . Patients evaluate disease response accord 2006 IWG response criterion MDS . This include evaluation alter natural history disease , cytogenic response hematologic improvement , quality life .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Diagnosis Low risk Intermediate1 risk MDS cytogenetic abnormality ( accord IPSS criterion ) ; patient must bone marrow biopsy/aspiration tumor tissue available within 1 month prior first dose collected Screening period . Patients &gt; 18 year Screening candidate hematopoietic cell transplantation . Received 1 prior line treatment ; typically erythroidstimulating agent ( ESAs ) . Red blood cell ( RBC ) transfusiondependent anemia treat discontinuation EPO . Transfusion dependence define requirement least 2 unit RBCs transfuse 8 week prior study initiation . Use recombinant EPO within 8 week prior screen . Patient concurrent active malignancy prior history malignancy MDS ( except basal cell squamous cell carcinoma skin situ cervix ) unless free disease least 1 year . Unstable cardiovascular function : Symptomatic ischemia , Uncontrolled clinically significant conduction abnormality ( i.e. , ventricular tachycardia antiarrhythmic agent exclude ; 1st degree atrioventricular ( AV ) block asymptomatic Left anterior fascicular block/Right bundle branch block ( LAFB/RBBB ) exclude ) , Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) Class â‰¥3 , myocardial infarction ( MI ) within 3 month . Uncontrolled infection require parenteral antibiotic , antiviral , antifungal within 1 week prior first dose . Infections control concurrent antimicrobial agent acceptable , antimicrobial prophylaxis per institutional guideline acceptable . Active bleeding Grade 34 , last 4 week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>KPT-330</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>Selinexor</keyword>
	<keyword>SIER</keyword>
	<keyword>Myelodysplastic Syndrome ( MDS )</keyword>
	<keyword>Erythropoietin ( EPO )</keyword>
	<keyword>Refractory</keyword>
</DOC>